Ethnobotany study and phytochemical screening of Caralluma europaea (Guss.) N.E. Br.
By: Nadia Sagou, Zineb Rhandour, Malak Eddebbagh, Mohamed Hsaine, Mohamed Berrada, Abdelmjid Abourriche, Ahmed Bennamara
Key Words: Caralluma europaea, Ethnobotanical study, Phytochemical screening
Int. J. Biosci. 9(6), 460-467, December 2016.Generate Certificate]
Natural substances derived from plants have multiple interests used in different industries. Moreover, the use of synthetic molecules is currently being called into question, because of the potential toxicological risks of these molecules. Now, new natural plant sources are being sought. The study of the pharmacological activities of plants has become a kind of fashion in the last decade, because of the socio-economic and cultural changes of consumers and industrialists over time; this has upset the scientific community and prompted it to investigate in this search axis. The ethno botanical information obtained from the traditional therapists of the big souk of the city of Marrakech and that of the city of Casablanca enabled us to note that the use of raw aerial parts in dried juice or powder mixed with honey from Caralluma europaea (Guss.), A medicinal plant belonging to the Apocynaceae family, locally known as “Daghmouss”, is highly appreciated by the local population for its therapeutic properties. Caralluma europaea (Guss.) is a spontaneous species, very widespread in mountainous regions of Morocco, contributes significantly to health care for the treatment of some diseases such as genital cysts, diabetes, goitres and kidney stones. Various phytochemical tests applied to the aqueous and organic extracts of the stems of Caralluma europaea (Guss.) have shown the presence of a few families of secondary chemical compounds, in particular polyphenols, flavonoids, tannins and alkaloids, known bioactive compounds for their phytochemical action Antibacterial and antifungal effects to anti-cancer and anti-tumor effects and because of which Caralluma europaea (Guss.) Has significant therapeutic potential that we plan to expand.